生殖器濕疣：新創療法、未滿足的需求和TPP洞察報告，2026年

市場概覽

• 法國生殖器濕疣市場預計將從 3.9 億美元成長到 5.7 億美元，反映出市場強勁擴張。
• 以下因素正在推動市場成長：
• 高復發率導致需要反覆治療。
• 持續使用基於治療的治療方法和局部療法
• 儘管已有預防性疫苗，但市場規模仍受到現有患者群體規模和治療需求的支持。
• 公眾意識的提高和篩檢發展，使得診斷率和治療率都得到了改善。
• 未來的市場動態將取決於疫苗接種率的提高和更永續治療方法的開發。

生殖器濕疣的新治療方法及對TPP的深入研究

Thelansis 的「生殖器濕疣：新興治療方法、未滿足的需求和目標產品概況 (TPP) 洞察報告 - 2026」對該適應症的關鍵新興治療方法和主要藥物開發機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、臨床試驗設計和關鍵意見領袖 (KOL) 的見解。

生殖器濕疣概述

生殖器濕疣（臨床上稱為尖形濕疣）是一種傳染性極強的良性肛門生殖器腫瘤，絕大多數是由低危險型人類乳突病毒（HPV）感染引起的，尤其是6型和11型。感染主要透過性交時黏膜和皮膚的直接接觸發生，病毒可深入基底角質細胞。雖然大多數免疫功能正常的個體能夠產生有效的細胞免疫反應並自發性清除病毒，但持續感染會導致顯著的細胞增殖。臨床上，生殖器疣表現為膚色、外生性、「菜花狀」丘疹或斑塊，但其明確的組織病理學特徵是存在病理生理學特異性的空泡細胞（具有染色過深、增大的細胞核和明顯的核週暈的鱗狀上皮細胞）。由於潛在的病毒庫往往在可見病灶消失後仍持續存在於鄰近正常組織中，因此臨床復發率極高。為此，治療方案採用階梯式方法，結合患者自行使用的免疫調節劑和抗有絲分裂藥物（如咪喹莫特和鬼臼樹脂）以及醫療專業人員實施的手術切除（如冷凍療法、三氯乙酸和手術切除），重點在於徹底清除肉眼可見的腫瘤並緩解症狀。最重要的是，目前全球標準治療方案優先考慮一級預防，利用高效的九價人類乳突病毒(HPV)疫苗有效中和這些病毒載體，顯著降低疾病發生率。

主要亮點

• 據預測，義大利生殖器濕疣病例數將從 945,224 例增加到 1,013,513 例，這表明儘管採取了疫苗接種措施，但該疾病的負擔仍在加重。
• 持續的病毒攜帶和根治性的治療方法意味著高復發率仍然是一個嚴峻的挑戰。
• 這種疾病不僅表現出臨床症狀，而且對心理社會方面和生活品質 (QOL) 也造成了重大負擔。
• 隨著人類乳突病毒(HPV)疫苗疫苗接種計劃的普及，預計感染率將逐漸下降，尤其是在年輕人中。
• 治療治療方法創新有限，凸顯了對永續的、以病毒為標靶的治療方法的持續未滿足需求。

透過對醫生和關鍵意見領袖 (KOL) 的調查所獲得的見解：

• 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更深入的見解，從而進一步完善了調查結果。
• 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

• PowerPoint簡報
• MS Excel

主要問題

• 詳細的競爭格局趨勢
• 管道分析
• 符合新興治療方法的患者
• 大公司
• 主要作用機制
• 發布日期預測等。
• 臨床試驗趨勢分析
• 目標患者群
• 試驗終點
• 測試設計
• 受試者招募標準等。
• 未滿足的需求和機遇
• 目前主要治療方法的有效性
• 未滿足需求的關鍵領域
• 主要未滿足需求的市場規模估算
• 目標產品概況
• 屬性和級別
• 醫生開立的處方
• 預期患者佔有率
• 關鍵意見領袖對領先新興治療方法的見解
• 意識
• 預期用途/處理線
• 學位旨在解決重大未滿足的需求
• KOL評論

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Merck Sharp &Dohme LLC
• Shanghai Bovax Biotechnology Co., Ltd.

目錄

第1章：主要調查結果和分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及關鍵意見領袖見解
• 新興治療方法
• 重點
• 診斷和治療過程/演算法
• 領先的新興治療方法—概述和關鍵意見領袖見解

第3章 產品屬性分析

• 重點
• 科學屬性
• 商業性屬性
• 產品定位

第4章：初步調查

• 目前治療狀態
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療環境
• 當前挑戰
• 未滿足的需求
• 新興治療方法
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療前景
• 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

• 新興治療方法的主要未滿足需求和未來成就
• TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

Genital Warts Emerging Therapy and TPP Insights

Thelansis's "Genital Warts Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Genital Warts Overview

Genital warts, clinically termed condylomata acuminata, are highly contagious, benign anogenital neoplasms overwhelmingly driven by infection with low-risk human papillomavirus (HPV) genotypes, specifically types 6 and 11. Transmitted primarily through direct mucocutaneous contact during sexual activity, the virus intimately infects the basal keratinocytes; while the vast majority of immunocompetent individuals mount an effective cellular immune response and spontaneously clear the virus, persistent infection induces profound cellular proliferation. Clinically presenting as flesh-colored, exophytic, "cauliflower-like" papules or plaques, definitive histopathological diagnosis is hallmarked by the pathognomonic presence of koilocytes-squamous epithelial cells demonstrating hyperchromatic, enlarged nuclei surrounded by distinct perinuclear halos. Because the underlying viral reservoir frequently persists in adjacent normal tissue despite visible lesion clearance, clinical recurrence rates are notoriously high. Consequently, the therapeutic paradigm strictly focuses on macroscopic tumor destruction and symptomatic relief, utilizing a stratified approach of patient-applied immunomodulatory or antimitotic agents (such as imiquimod or podofilox) and provider-administered ablative interventions (including cryotherapy, trichloroacetic acid, or surgical excision). Most importantly, the global standard of care now heavily prioritizes primary prevention, leveraging the highly efficacious prophylactic 9-valent HPV vaccine to robustly neutralize these viral vectors and profoundly curtail disease incidence.

Key Highlights

• In Italy, prevalent cases of genital warts are projected to increase from 945,224 to 1,013,513, indicating a growing disease burden despite vaccination efforts.
• High recurrence rates remain a defining challenge due to persistent viral reservoirs and non-curative treatment approaches.
• The disease carries a significant psychosocial and quality-of-life burden, beyond its clinical manifestation.
• Increasing uptake of HPV vaccination programs is expected to gradually reduce incidence, particularly in younger populations.
• Limited innovation in curative therapies highlights a continued unmet need for durable and virus-targeting treatments.

Market Overview

• The France genital warts market is projected to grow from $390M to $570M, reflecting strong market expansion.
• Market growth is driven by:
• High recurrence leading to repeat treatment cycles
• Continued use of procedure-based and topical therapies
• Despite preventive vaccination, market value remains supported by existing prevalent patient pool and treatment demand.
• Increasing awareness and screening contribute to higher diagnosis and treatment rates.
• Future market dynamics will depend on vaccination coverage expansion and development of more durable therapeutic options.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Merck Sharp & Dohme LLC
• Shanghai Bovax Biotechnology Co., Ltd.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)